北美与欧洲致心律失常性右室心肌病植入式心律转复除颤器使用差异
结果显示北美患者接受一级预防ICD的可能性是欧洲患者的3倍以上,但持续性室性心律失常风险仅轻度升高;未植入ICD的北美患者室性心律失常风险高于欧洲患者。
要点
- 北美ARVC患者一级预防ICD植入率显著高于欧洲,各风险分层均如此。
- 调整基线危险因素后,北美患者接受ICD的HR为3.1(95%CI 2.5-3.8)。
- 欧洲ICD植入率较低并未伴随未植入ICD患者室性心律失常事件率升高。
核心结论
- 北美ARVC患者在各心律失常风险分层中接受一级预防ICD的比例均显著高于欧洲患者。
- 欧洲较低的ICD植入率并未导致未植入ICD患者室性心律失常事件率升高。
研究设计与样本
- 回顾性分析欧洲和北美11个国家临床注册中未发生持续性室性心律失常的ARVC患者。
- 按治疗地区分为北美组和欧洲组,并按基线预测的5年室性心律失常风险分为低危(<10%)、中危(10%-25%)和高危(>25%)三层。
主要发现
- 554例(50.5%)接受了 一级预防ICD,286例(26.0%)发生首次室性心律失常事件。
- 调整基线危险因素后,北美患者接受ICD的可能性是欧洲患者的3.1倍(HR 3.1,95%CI 2.5-3.8)。
- 北美患者发生持续性室性心律失常的风险仅轻度升高(HR 1.4,95%CI 1.1-1.8)。
- 未植入ICD的北美患者发生持续性室性心律失常的风险高于欧洲患者(HR 2.1,95%CI 1.3-3.4)。
临床怎么用
- 在ARVC一级预防ICD决策中,应关注跨地域实践差异,结合患者个体基线风险综合评估。
- 欧洲较低ICD植入率未伴随未植入者室性心律失常事件增加,提示需审慎评估ICD适应证。
局限性
- 本研究为回顾性注册分析,可能存在选择偏倚和未测量混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Implantable cardioverter-defibrillators (ICDs) are critical for preventing sudden cardiac death (SCD) in arrhythmogenic right ventricular cardiomyopathy (ARVC). This study aims to identify cross-continental differences in utilization of primary prevention ICDs and survival free from sustained ventricular arrhythmia (VA) in ARVC. METHODS: This was a retrospective analysis of ARVC patients without prior VA enrolled in clinical registries from 11 countries throughout Europe and North America. Patients were classified according to whether they received treatment in North America or Europe and were further stratified by baseline predicted VA risk into low- (<10%/5 years), intermediate- (10%-25%/5 years), and high-risk (>25%/5 years) groups. Differences in ICD implantation and survival free from sustained VA events (including appropriate ICD therapy) were assessed. RESULTS: One thousand ninety-eight patients were followed for a median of 5.1 years; 554 (50.5%) received a primary prevention ICD, and 286 (26.0%) experienced a first VA event. After adjusting for baseline risk factors, North Americans were more than three times as likely to receive ICDs {hazard ratio (HR) 3.1 [95% confidence interval (CI) 2.5, 3.8]} but had only mildly increased risk for incident sustained VA [HR 1.4 (95% CI 1.1, 1.8)]. North Americans without ICDs were at higher risk for incident sustained VA [HR 2.1 (95% CI 1.3, 3.4)] than Europeans. CONCLUSIONS: North American ARVC patients were substantially more likely than Europeans to receive primary prevention ICDs across all arrhythmic risk strata. A lower rate of ICD implantation in Europe was not associated with a higher rate of VA events in those without ICDs.
引用
- Carrick RT, De Marco C, Gasperetti A, et al. Implantable cardioverter defibrillator use in arrhythmogenic right ventricular cardiomyopathy in North America and Europe. Eur Heart J. 2024. PMID: 38195003. doi:10.1093/eurheartj/ehad799
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。